ArticleVeterinary sciences2025
Influence of Prednisolone Treatment on Serum Bile Acid Concentrations in Cats.
Article in Veterinary sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While corticosteroids affect bile acid metabolism in humans and dogs, their impact on serum bile acids in cats is unknown. Moreover, the early effects of corticosteroids on liver enzyme activity in cats are not well understood. We prospectively studied seven healthy cats (4-7 years) treated with oral prednisolone (1.1-1.5 mg/kg, median 1.28 mg/kg PO daily) for 7 days. Serum bile acids and liver enzyme activities (ALT, AST, ALP, GGT) were measured before treatment (day 0) and at days 2, 3, 8, 10, and 14. Statistical analysis used the Friedman test with post hoc comparisons to baseline. At baseline, bile acids were within reference interval (1-6.5 μmol/L) (median 2.1 μmol/L, range 1-3.2) and increased significantly during treatment with prednisolone to a median of 5.3 μmol/L (range 1.8-8.7) at d8, but remained below clinically abnormal levels. In contrast, AST, ALT, and ALP activities decreased significantly during prednisolone administration. GGT activities were undetectable at all times. We conclude that, although prednisolone significantly affected bile acids, the effect is likely of limited clinical relevance, as increases were minimal and remained below thresholds considered abnormal. Unexpectedly, transaminase and alkaline phosphatase activities decreased in the first days after administration. The reasons for this remain unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.